Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ocugen, Inc. - Common Stock (NQ:OCGN)

1.140 -0.010 (-0.87%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ocugen, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
WHY: NEW YORK, NY - (NewMediaWire) - April 16, 2024 - Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Ocugen,... 
Via TheNewswire.com
Topics Lawsuit
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
From Schall Law
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Chemours, and Ocugen and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
WHY: NEW YORK, NY - (NewMediaWire) - April 15, 2024 - Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Ocugen,... 
Via TheNewswire.com
Topics Lawsuit
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
WHY: NEW YORK, NY - (NewMediaWire) - April 13, 2024 - Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Ocugen,... 
Via TheNewswire.com
Topics Lawsuit
ROSEN, A LONGSTANDING LAW FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
ROSEN, A LONGSTANDING LAW FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
WHY: NEW YORK, NY - (NewMediaWire) - April 12, 2024 - Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Ocugen,... 
Via TheNewswire.com
Topics Lawsuit
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Ocugen, Inc. (OCGN) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
From Ocugen
Via GlobeNewswire
OCUGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Ocugen, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
From Schall Law
Via GlobeNewswire
Stockholder Alert: Robbins LLP Informs Investors of the Class Action Filed Against Ocugen, Inc. (OCGN)
From Robbins LLP
Via GlobeNewswire
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Ocugen, Inc. Incorporated Investors – OCGN
From Rosen Law Firm
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Ocugen, Inc. (OCGN) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
From Ocugen
Via GlobeNewswire
OCUGEN LOSS ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Inquire About Securities Class Action Investigation – OCGN
From The Rosen Law Firm, P.A.
Via Business Wire
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
From Ocugen
Via GlobeNewswire
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy
From Ocugen
Via GlobeNewswire
OCUGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Ocugen, Inc. on Behalf of Ocugen Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Ocugen Provides Business Update with Certain Financials for the Year Ending 2023
Conference Call and Webcast Today at 8:30 a.m. ET 
From Ocugen
Via GlobeNewswire
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease
From Ocugen
Via GlobeNewswire
Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023
From Ocugen
Via GlobeNewswire
Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer
From Ocugen
Via GlobeNewswire
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410
From Ocugen
Via GlobeNewswire
Ocugen to Present at Investing in Cures Summit
From Ocugen
Via GlobeNewswire
Medical Breakthrough Stocks Under $1: OCGN, VERO, RSCI, VTAK, ENVB
Via AB Newswire
Topics Intellectual Property
Ocugen Clinical Showcase Webcast Now Available
From Ocugen
Via GlobeNewswire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.